Background: Expression of individual oncogenes may predict outcome in patients with metastatic colorectal cancer (CRC). We studied the oncogene profile in the tumors of patients with CRC and assessed their value as predictors of liver metastases.
Methods: The oncoproteins c-myc, c-erbB-2/neu (c-neu), PCNA and p53, were measured by immunohistochemistry in sections of metastasizing human CRC (n=34) and their liver secondaries as well as in sections of nonmetastasizing CRC (n=25).
Results: The metastasizing primary CRC expressed proliferating-cell nuclear antigen (PCNA), c-neu, and c-myc at significantly higher levels than the nonmetastasizing primary cancer. p53 was also overexpressed in the metastatic group compared with the nonmetastasizing CRC, but this difference was not significant. The frequency of expression of all these markers was similar in the metastasizing primary CRC and the liver secondaries from the same patients. There was no correlation between the expression of the individual markers and histological grade, DNA ploidy, and subsequent local recurrence and lung metastasis and survival. However, when both groups were assessed together, positive expression of c-myc was more likely to occur in poorly differentiated tumors, whereas PCNA expression increased with more advanced Dukes stages.
Conclusion: These results suggest that the overexpression of c-myc, c-neu, PCNA, and p53 may occur in CRC that are likely to metastasise to the liver.
Oncorprotein c-mycc-erbB-2/neuPCNA p53 Metastatic colorectal cancer
Rigas B. Oncogenes and suppressor genes: their involvement in colon cancer.J Clin Gastroenterol 1990;12:494–9.PubMedGoogle Scholar
Menko FH.Genetics of colorectal cancer for clinical practice. The Netherlands: Kluwer Academic Publishers, 1993:135–6.Google Scholar
Jen J, Kim H, Piantadosi S, Liu ZF, Levitt RC, Sistonen P, Kinzler KW, et al. Allelic loss of chromosome 18q and prognosis in colorectal cancer.N Engl J Med 1994;331:213–21.CrossRefPubMedGoogle Scholar
Yang J-L, Crowe PJ, Ow KT, Ham JM, Crouch RL, Russell PJ. DNA flow-cytometric analysis in colorectal cancer: a comparison of metastasising and non-metastasising tumours.J Gastroenterol Hepatol (in press).Google Scholar
Kerbel RS. Growth dominance of the metastatic cancer cell: cellular and molecular aspects.Adv Cancer Res 1990;55:87–131.PubMedGoogle Scholar
Goh HS, Soong TW, Lee YS, Ho J, Goh CR. c-myc oncogene expression in colorectal cancer: its use in prognosis and role in colorectal carcinogenesis.Ann Acad Med Singapore 1990;19:139–41.PubMedGoogle Scholar
Yamaguchi A, Ninomiya I, Ishida T, Nishimura G, Kanno M, Yonemura Y, Miwa K, et al. Immunohistochemical detection of c-myc products in colorectal cancer and proliferative cell rate.Oncology 1992;49:40–4.PubMedGoogle Scholar
Rowley S, Newbold KM, Gearty J, Keighley MR, Donovan IA, Neoptolemos JP. Comparison of deoxyribonucleic acid ploidy and nuclear expressed p62 c-myc oncogene in the prognosis of colorectal cancer.World J Surg 1990;14:545–50.CrossRefPubMedGoogle Scholar
Kozma L, Kiss I, Szakall S, Ember I. Investigation of c-myc oncogene amplification in colorectal cancer.Cancer Lett 1994;81:165–9.CrossRefPubMedGoogle Scholar
Kapitanovic S, Spaventi R, Poljak L, Kapitanovic M, Pavelic ZP, Gluckman JL, Spaventi S, Pavelic K. High c-erbB-2 protein level in colorectal adenocarcinomas correlates with clinical parameters.Cancer Detec Prevent 1994;18:97–101.Google Scholar
Omori K. DNA content and c-erbB-2 oncoprotein expression in hepatic metastases from colorectal carcinoma in relation to clinicopathologic findings and prognosis.Jpn J Surg 1991;92:1469–79.Google Scholar
Tsioulias GJ, Muto T, Morioka Y, Yamamoto T, Mori S. erbB-2 gene expression in colorectal cancer.Jpn J Exp Med 1990;60:343–9.PubMedGoogle Scholar
Risio M, Rossini FP. Cell proliferation in colorectal adenomas containing invasive carcinoma.Anticancer Res 1993;13:43–7.PubMedGoogle Scholar
Jin Y, Jin Z, Sawada T, Kubota Y, Suzuki K, Watanabe T, Sameshima S, et al. Growth type of colorectal cancer invasion of the proper muscle in relation to DNA ploidy and distribution of PCNA.Jpn J Cancer Chemother 1993;20:784–7.Google Scholar
Mayer A, Takimoto M, Fritz E, Schellander G, Kofler K, Ludwig H. The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer.Cancer 1993;71:2454–60.PubMedGoogle Scholar
Al-Sheneber IF, Shibata HR, Sampalis J, Jothy S. Prognostic significance of proliferating cell nuclear antigen expression in colorectal cancer.Cancer 1993;71:1954–9.PubMedGoogle Scholar
Schneider BG, Hilsenbeck SG, Hensel CH, Pekkel V, Shelton CH, Rodriguez-Martinnez HA, Gutierrez-Diaz ME, et al. p53 mutations in gastric and colorectal cancers in Texas Hispanics versus Anglos.Virchows Arch 1994;424:187–93.CrossRefPubMedGoogle Scholar
Baba S, Ogiwara H, Nakamura T, Teramoto T. Extended lymphadenectomy and the quality of life in rectal cancer patients.Int Surg 1994;79:23–6.PubMedGoogle Scholar
Suzuki H, Matsumoto K, Koide A, Tada T, Fujin I, Okuda A, Shigemori C. Correlation of p53 with the clinicopathologic features and prognosis of colorectal adenocarcinoma.Surg Today 1994;24:85–7.PubMedGoogle Scholar
Nathanson SD, Linden MD, Tender P, Zarbo RJ, Jacobsen G, Nelson LT. Relationship among p53, stage, and prognosis of large bowel cancer.Dis Colon Rectum 1994;37:527–34.CrossRefPubMedGoogle Scholar
Hamelin R, Laurent-Puig P, Olschwang S, Jego N, Asselain B, Remvikos Y, Girodet J, Salmon RJ, Thomas G. Association of p53 mutations with short survival in colorectal cancer.Gastroenterology 1994;106:42–8.PubMedGoogle Scholar
Zhau HE, Pisters LL, Hall MC, Zhao LS, Troncoso P, Pollack A, Chung LW. Bio-markers associated with prostate cancer progression.J Cellular Biochem Suppl 1994;19:208–16.Google Scholar
Berger MS, Locher GW, Saurer S, Gullick WL, Waterfield MD, Groner B, Hynes NE. Correlation of c-erbB-2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading.Cancer Res 1988;48:1238–43.PubMedGoogle Scholar
Williams AR, Piris J, Wyllie AH. Immunohistochemical demonstration of altered intracellular localization of the c-myc oncogene product in human colorectal cancer neoplasms.J Pathol 1990;160:287–93.CrossRefPubMedGoogle Scholar
Fisher CJ, Gillett CE, Vojtesek B, Barnes DM, Millis RR. Problems with p53 immunohistochemical staining: the effect of fixation and variation in the methods of evaluation.Br J Cancer 1994;69:26–31.PubMedGoogle Scholar